导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 9.00% | 784/4773 |
| 近一周 | -3.90% | 4679/5462 |
| 近一月 | -1.24% | 888/5421 |
| 近一季 | -6.02% | 1969/5209 |
| 近半年 | -12.45% | 3783/4920 |
| 近一年 | 23.03% | 325/4366 |
| 近两年 | 78.55% | 827/2954 |
| 近三年 | 59.27% | 453/2253 |
| 成立以来 | 92.32% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
10.92% 48/4961 |
-1.23% 3341/5312 |
- - |
- - |
| 2025 | 41.00% 751/4813 |
-0.34% 2209/3635 |
2.95% 1238/4076 |
25.61% 1385/4524 |
9.40% 193/4813 |
| 2024 | 9.28% 1480/3463 |
8.29% 192/2808 |
-1.26% 1007/3014 |
10.53% 2615/3129 |
-7.54% 2771/3463 |
| 2023 | -0.25% 443/2656 |
5.56% 771/2280 |
-5.96% 1566/2385 |
3.61% 180/2515 |
-3.00% 572/2655 |
| 2022 | -8.14% 153/2207 |
0.37% 112/1919 |
6.07% 772/2016 |
-8.81% 227/2113 |
-5.37% 1926/2208 |
| 2021 | 40.85% 28/1822 |
3.51% 173/1255 |
9.72% 529/1330 |
32.98% 9/1466 |
-6.74% 1548/1822 |
| 2020 | 40.75% 303/1250 |
-12.70% 896/1028 |
8.89% 809/1067 |
22.24% 34/1164 |
21.14% 58/1184 |
| 2019 | 25.72% 593/1092 |
21.63% 596/754 |
-2.38% 349/804 |
-4.58% 779/850 |
10.98% 86/918 |
| 2018 | -31.34% 493/834 |
- - |
- - |
- - |
-16.96% 645/691 |
| 2017 | 19.34% 194/714 |
- - |
- - |
- - |
- - |
| 2016 | -7.70% 227/605 |
- - |
- - |
- - |
- - |
| 2015 | 1.19% 246/575 |
- - |
- - |
- - |
- - |
| 2014 | 28.05% 173/237 |
- - |
- - |
- - |
- - |
| 2013 | -34.87% 183/186 |
- - |
- - |
- - |
- - |
| 2012 | 4.97% 79/140 |
- - |
- - |
- - |
- - |
| 2011 | -34.68% 101/102 |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 国联安上证商品ETF VS. 长安沪深300非周期A(740101) |